Antagonism of protein-protein interactions (PPIs) with small molecules is increasingly considered as a viable therapeutic strategy . Successful PPI inhibitors tend to target proteins that possess deep partner-binding pockets rather than the flat protein interacting surfaces. The WD40 repeat (WDR) domain-containing proteins comprise one of the most abundant PPI domains in the human proteome, playing crucial roles in various cellular processes, including numerous disease-associated mechanisms . Despite lacking clinical validation, WDR5, a novel target with cautious optimism for the treatment of leukemia and other cancer types, has garnered significant attention . Multiple efforts have been undertaken to discover binders for the two distinct peptide-binding pockets present on this scaffold protein, the WIN (WDR5-interacting) pocket and the WBM (WDR5-binding motif) pocket . The protooncogene MYC interacts with WDR5 on the WBM interface , making it a great drug target for employing a 3D generative modeling approach. The aim is to enable the structural diversity of hits, thereby expanding drug discovery efforts for MYC through this co-factor .